ARQT
Arcutis Biotherapeutics Inc.
Company Overview
| Mkt Cap | $2.50B | Price | $23.27 |
| Volume | 775.03K | Change | +0.00% |
| P/E Ratio | -17.9 | Open | $23.47 |
| Revenue | $166.5M | Prev Close | $23.27 |
| Net Income | $-140.0M | 52W Range | $11.86 - $31.77 |
| Div Yield | N/A | Target | $34.75 |
| Overall | 39 | Value | 40 |
| Quality | 52 | Technical | 27 |
No chart data available
About Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Latest News
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARQT | $23.27 | 0% | 775.03K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arcutis Biotherapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW